GlassScriptPhysician profile
April Hurley
NPI 1427489640
$2,000.59
in general payments reported to CMS, 2019-2025
31 companies · $381 in 2025
The $381 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $451 · 2022: $300 · 2023: $438 · 2024: $430 · 2025: $381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,249.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $257.54 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Otsuka America Pharmaceutical, INC. | $223.34 | 2023-2025 | Rexulti, Nuedexta |
| Lilly USA, LLC | $173.74 | 2021-2025 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $146.47 | 2021-2023 | Myrbetriq, Veozah |
| Janssen Pharmaceuticals, INC | $142.71 | 2021-2024 | Spravato |
| Vanda Pharmaceuticals INC. | $134.84 | 2024-2025 | Hetlioz, Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $108.65 | 2021-2025 | Caplyta |
| Merck Sharp & Dohme LLC | $97.31 | 2021-2024 | Vaxneuvance, Gardasil 9, Vaxelis |
| Lundbeck LLC | $87.43 | 2022-2023 | Rexulti |
| Abbott Laboratories | $72.24 | 2022-2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Axsome Therapeutics, INC. | $71.47 | 2023-2024 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $45.84 | 2023-2025 | Austedo Xr, Austedo, Austedo Xr |
| Avanir Pharmaceuticals, INC. | $44.94 | 2022 | |
| Alexion Pharmaceuticals, INC. | $43.10 | 2021 | |
| Abbvie INC. | $40.96 | 2021-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $33.53 | 2025 | Endurant Iis |
| Neurocrine Biosciences, INC. | $28.52 | 2023-2025 | Ingrezza |
| Astrazeneca Pharmaceuticals LP | $27.83 | 2021-2024 | Farxiga |
| Biogen, INC. | $26.56 | 2025 | Zurzuvae |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.81 | 2021 | |
| Ironshore Pharmaceuticals INC. | $20.19 | 2023 | Jornay Pm |
| Alkermes, INC. | $17.78 | 2023 | Lybalvi |
| Eisai INC. | $17.25 | 2021 | |
| Mylan Specialty L.P. | $16.13 | 2021 | |
| Pfizer INC. | $16.00 | 2021 | |
| Collegium Pharmaceutical, INC. | $15.20 | 2021 | |
| Glaxosmithkline, LLC. | $14.76 | 2023 | Shingrix, Arexvy |
| Almatica Pharma LLC | $14.27 | 2024 | Loreev Xr |
| Novartis Pharmaceuticals Corporation | $13.60 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.42 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw April Hurley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.